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Abstract Molecularly targeted therapies promise to
transform the treatment of cancer patients, including those
with brain tumors. A deeper understanding of the biology
of brain tumors has led to a palpable excitement that new
and more effective treatments are on the horizon for these
deadly diseases. This conference brought basic, genomic,
and translational scientists together with clinicians to dis-
cuss how to develop more effective molecularly targeted
therapies for brain tumor patients based on a mechanistic
understanding of the molecular circuitry and biology of the
disease.
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Advances in surgical management of gliomas
In this session, Mitchel S. Berger, (University of California
San Francisco, San Francisco, USA) presented the data on
how surgery for brain cancer can be safe, minimizing
morbidity, and providing the scientiﬁc specimens for
molecular and genetic study and analysis. He reviewed his
experience with modern imaging modalities, language
mapping, gross total resection of gliomas to demonstrate
that gliomas can be resected safely. Until recently, domi-
nant side craniotomies required generous craniotomy and a
wide margin around eloquent cortex, but these advances
have allowed for smaller craniotomy and more precise
tumor resection around eloquent cortex [1]. An important
point in his presentation was the observation that higher
volume tumor centers will become more important as these
centers are associated with decreased morbidity for tumor
resections. Furthermore, Dr. Berger and colleagues have
shown that aggressive surgical resection of low grade
gliomas may have a signiﬁcant improvement on survival
outcomes and alter the natural history of malignant trans-
formation of these low grade gliomas. This ﬁnding sug-
gests that aggressive surgical resection may contribute
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suggested that targeted therapeutics may be most effective
after aggressive and safe surgical resection which leaves
the least amount of residual disease for the therapy to
target.
Current status of targeted therapies in malignant
gliomas
W. K. Alfred Yung (University of Texas M.D. Anderson
Cancer Center, Houston, USA) discussed the current status
of various targeted therapeutics against glioblastomas and
indicated that there still remained signiﬁcant improvements
that have yet to be achieved. His summary of targeted
therapeutics identiﬁed several key components of targeted
treatments against brain cancer: (1) identifying the targets,
(2) recognizing that these targets are drivers of cancer
phenotype, (3) developing drugs against these targets,
(4) improved biomarkers to characterize the presence of
these targets, and (5) delivery of these focused drugs
against these targets. He strongly suggested that targeted
therapeutics have been less successful because of the
myriad of molecular heterogeneity and overlapping regu-
latory pathways. His review of the EGFR and VEGF data
suggested that the signaling and targeting of these signal
pathways is complicated and not a simple task. His data
from the M.D. Anderson group demonstrated in an animal
model that anti-VEGF therapy may ultimately drive the
tumor to develop a more invasive resistant phenotype. In
summary, he recognized several obstacles to improving
targeted therapies: (1) multiple activated pathways,
(2) compensatory pathways, (3) resistant phenotypes, and
(4) delivery mechanisms to the brain cancer. Future indi-
vidualized targeted therapy designs with molecular sur-
veillance imaging may lead to overcoming some of these
obstacles against targeted therapeutics.
Targeting signal transduction pathways in brain cancer
In this session, Paul S. Mischel (University of California
Los Angeles, Los Angeles, USA) discussed the important
role that pathologists will play in identifying the underlying
molecular and genetic defects that comprise glioblastomas.
He reviewed the importance of knowing the critical parts of
signaling pathways, but also suggested that knowing these
critical steps in signal transduction pathways does not
make altering these pathways any easier. Dr. Mischel
suggested that the future of improved cancer genetic
analysis will lead to personalized and individualized
medicine based on the suite of molecular alterations pres-
ent in each patient’s tumor [3]. Dr. Mischel stressed the
importance of integrating functional and genomic studies,
citing the EGFR/PI3K signaling network as an example.
He showed how attempts to inhibit EGFR/PI3/MTOR
signaling in glioblastoma patients have failed due to PTEN
loss, co-activation of other receptor tyrosine kinases, and
activation of feedback loops to maintain signal ﬂux through
the PI3K pathway. Thus, understanding the critical com-
ponents is not sufﬁcient; understanding how they function
together is needed. Interestingly, it was also discussed that
intra-tumor cellular and molecular heterogeneity are
potentially responsible for promoting resistance to targeted
therapies [4], and the current suite of technologies is not
well-suited to dissect this heterogeneity. He provided an
example of one type of technology that can potentially be
used to capture deﬁned cell populations directly from
clinical samples for in-depth molecular analysis.
Special: Point-Counterpoint
Chaired by Mitchel S. Berger, (University of California
San Francisco, USA).
EGFR targeting in malignant glioma: translational
and clinical implications
Dr. Michael Prados, (University of California San Fran-
cisco, San Francisco, USA) presented his point that early
phase clinical trials have shown ambiguous results target-
ing EGFR and that these ambiguous results make it hard to
know which targets to aim for and which modalities to
utilize in chasing after these various targets. EGFR was
identiﬁed to be ampliﬁed or over expressed in many glio-
mas, and pre-clinical and early phase trials led to the Phase
2 evaluation of erlotnib versus temozolomide or carmustine
in recurrent glioblastoma. These brain tumor group clinical
trials of erlotnib demonstrated no signiﬁcant improvement
in survival [5]. Retrospective evaluation of targeting EGFR
has shown meager results, and the use of EGFR inhibitors
has become less utilized by neuro-oncologists. This less
then encouraging experience has raised doubts in the
applicability of pre-clinical data to predict clinical appli-
cations and asks whether we have identiﬁed the critical
prognostic factors or are utilizing inappropriate pre-clinical
models for developing translational and developmental
therapeutics.
Targeted therapy clinical trials in glioblastoma:
an opportunity to learn from failure?
For the counterpoint, Dr. Timothy Cloughesy (University
California Los Angeles, Los Angeles, CA) discussed that
over the past decade, numerous investigators, and the
TCGA, have provided whole genome evaluation of gene
expression, DNA copy number and selected sequencing of
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pathways in glioblastoma likely responsible for tumori-
genesis and progression. The past decade also provided the
opportunity to evaluate various targeted therapies focused
upon inhibiting these altered signals. These clinical eval-
uations include inhibition of various receptor tyrosine
kinases, as well as inhibiting, presumably important,
downstream nodes of these receptors. However, with few
exceptions, these investigations have failed to achieve
stated clinical objectives (response rate, progression free
survival, and overall survival), which has made the end
goal of personalized medicine, based upon the molecular
make up of the tumor, elusive [6]. Improving our under-
standing of these failed clinical evaluations will provide
guidance toward the effective development of targeted
agents in glioblastoma. To be successful, we will need to
change our clinical evaluation paradigm to include
obtaining tissue during drug delivery. Additionally, we
need to develop technologies for improved tissue evalua-
tions in order to anticipate molecular adaptations, feedback
loops, and tumor heterogeneity, potentially on the single
cell level. Finally, we need to promote the cooperation of
drug developers toward the development of potent selec-
tive inhibitors and combination therapies.
Session 1: Pediatric brain tumors: Developmental
origin and clinical implications
Chaired by Cameron W. Brennan (Memorial Sloan-
Kettering Cancer Center, New York, NY).
Developmental biology of pediatric brain cancer
Dr. David H. Rowitch (University of California San
Francisco, San Francisco, CA) presented data indicating
that the bHLH transcription factor Olig2 is critical and
required for the gliomagenesis of astrocytomas. His data
suggested that Olig2 is expressed in all adult and pediatric
gliomas and is an inducible pathway for gliomagenesis by
opposing the action of p53. Olig2 may interfere with the
interactions of p53 binding to p21 cis acting DNA regu-
latory sequences. This may provide an attractive target for
anti-tumor therapies by aiming for this molecular target of
Olig2 [7]. Dr. Rowitch also reported some data from a
large genomic study of pediatric tumors, which indicated
that BRAF V600 mutations may play a critical role in
gliomagenesis. His work with mice models suggests that
BRAF V600 mutation coupling with Ink4a/Arf deletions
may be obligatory to gliomagenesis. These ﬁndings may
provide novel intracellular and signaling targets for the
development of anti-tumor therapeutics for pediatric brain
tumors.
Cellular and molecular origin of embryonal brain tumors
In this session, Dr. Charles G. Eberhart (Johns Hopkins
University School of Medicine, Baltimore, MD) reviewed
medulloblastoma and CNS PNET. Medulloblastomas
appear to originate from both the external germinal layer
(EGL) of the cerebellum and stem cells in other regions
such as the ventricular zone. Tumors arising from the EGL
generally feature high levels of Hedgehog signaling. In
contrast, medulloblastoma with active Wnt signaling
express ventricular zone markers and are associated with
better clinical outcomes. In one recent analysis, both the
Hedgehog and Wnt medulloblastoma subgroups showed
signs of Notch activity, and crosstalk between Notch and
Hedgehog may play a role in the emergence of therapeutic
resistance when such pathways are targeted in medullo-
blastoma or glioblastoma. Additional medulloblastoma
subgroups with poor clinical outcomes tend to have ana-
plastic histology and show elevated expression of MYCC
and genes associated with phototransduction and semaph-
orin signaling. CNS PNET are also becoming more pre-
cisely subcategorized by paired microscopic and genetic
analyses. One relatively common subtype, known as
embryonal tumor with abundant neuropil and true rosettes
(ETANTR), appears to be deﬁned molecularly by an
amplicon at chromosome 19q13 resulting in overexpres-
sion of speciﬁc microRNAs [8]. In summary, medullo-
blastoma and CNS PNET are molecularly heterogeneous
and contain multiple genetically and clinically distinct
subgroups. Developmentally signiﬁcant signaling pathways
are frequently activated in embryonal tumors and represent
potential therapeutic targets. However, accurate molecular
subclassiﬁcation of embryonal tumor subtypes will be
critical for the development of effective targeted therapies.
Pediatric brain tumors: it is all about where they are born
Dr. Richard J. Gilbertson (St. Jude Children’s Research
Hospital, Memphis, TN) reviewed the heterogeneity in
clinically deﬁned ependymomas and medulloblastomas
that present a clinical challenge, especially in the pediatric
population [9]. His data suggests that radial glia may play a
critical role in the development of ependymomas and that
recent transcriptomes of human ependymomas match spe-
ciﬁc variants of neural stem cells. Their animal model of a
mouse ependymoma can model a human subgroup of
ependymoma from which novel targets can be studied.
Lastly, he reviewed the Wnt class of medulloblastomas
which may arise from the ventricular region cells in
contrast to the hedgehog activated, external germinal
derived medulloblastoma. This Wnt induced pathway
may represent a distinct subgroup of tumors which can
be effectively modeled and molecularly targeted. His
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gene, through beta-catenin expression, likely induces
hyperplasia and medulloblastoma formation through the
Wnt signaling system.
Deﬁning the permissive microenvironment
in pediatric glioma
In his proffered talk, Dr. David H. Gutmann (Washington
University School of Medicine, Saint Louis, MO) sug-
gested that pediatric gliomas are markedly different from
adult gliomas, because pediatric brain tumors are more
related and similar to the steps of normal brain develop-
ment in their response to extracellular signals. The cellular
and molecular heterogeneity inherent in pediatric brain
tumors highlight the importance of non-neoplastic ele-
ments in these tumors. His work on neuroﬁbromatosis-1
(NF1) has led to a better understanding pediatric gliomas
[10]. He reported that Nf1 loss of heterozygosity in the
non-neoplastic tumor microenvironment provides a per-
missive condition in cooperation with complete Nf1 inac-
tivation in glia to facilitate tumorigenesis. Moreover, he
showed that resident microglia in these tumors are critical
for tumor growth in genetically-engineered mice in vivo,
supporting the notion that non-neoplastic stromal cells
provide instructive cues important for brain tumor devel-
opment and maintenance in children.
Session 2: Adult brain tumors: Developmental origin
and clinical implications
Chaired by Paul S. Mischel (David Geffen School of
Medicine at UCLA, Los Angeles, CA).
Receptor signaling and tumor heterogeneity
In this session, Dr. Webster K. Cavenee (Ludwig Institute,
University of California San Diego, La Jolla, CA) postu-
lated that tumor heterogeneity in glioblastoma is an active
process driven by a mutant EGFR-induced paracrine cir-
cuit. His data from primary GBM samples showed that
tumors expressing EGFRvIII usually do so in a small
proportion of cells and are usually surrounded by tumor
cells expressing wild-type EGFR [11]. In xenograft studies,
this mutant EGFR enhanced the growth of wild-type
EGFR-expressing tumor cells and suggested an active
process of interaction between these two different sub-
populations of tumor cells. By transferring media condi-
tioned by mutant EGFR to wild-type EGFR cells, the same
effect could be seen in wild-type EGFR growth and pro-
liferation. Dr. Cavenee demonstrated that EGFR mutant
cells do not secrete EGFR ligands, but rather secrete a
STAT upregulating signal that can be inhibited if the
cytokine receptor, GP130, is blocked. Hence this active
interaction driven by the mutant EGFR receptor is a trans
method for signaling though cytokines such as IL6 and LIF
that also actively maintains this heterogeneity in glioblas-
toma. The smaller population of EGFR mutant cells can
help drive the heterogeneity and growth of gliomas, and
may represent a cancer cell–cell interaction that could be a
target of therapeutic signiﬁcance.
Some human cancers have extraordinary high
frequencies of tumorigenic cells
Dr. Sean J. Morrison (University of Michigan Medical
School, Ann Arbor, MI) presented data that suggest while
some cancers follow the cancer stem cell model, other
tumors may have common tumorigenic cells with little sign
of hierarchical organization. He reported that some PTEN
leukemias follow the cancer stem cell model with a small
proportion of these cells being tumorigenic [12]. On the
other hand, metastatic melanoma has a much higher fre-
quency of tumorigenic cells and does not follow the cancer
stem cell model. Heterogeneity is not necessarily a hall-
mark of hierarchy or the stem cell model, and cancers need
not be hierarchically organized in order to be heteroge-
neous. Furthermore, he stated that tumor growth rate does
not correlate with the frequency of tumorigenic cells in
melanoma. With regard to gliomas, he hypothesized that
there are intrinsic differences in cancers that are not
relatable to stem cells. His preliminary data in mice sug-
gested that tumorigenic cells are common in some glio-
blastomas similar to melanoma, and that CD133 did not
distinguish between tumorigenic and non-tumorigenic
cells in some of these tumors. Some glioblastomas may
be similar to melanoma with a high percentage of non-
stem-like tumorigenic cells.
Dual role of primary cilia in medulloblastoma
In this session, Dr. Arturo Alvarez-Buylla (University of
California San Francisco, San Francisco, CA) reviewed the
2 neural stem cell regions in the subventricular zone and
the hippocampus. His data revealing the pinwheel archi-
tecture of the ventricular surface was reported. Focusing on
medulloblastoma development, his work focuses on the
role of primary cilia in tumorigenesis and demonstrated the
importance of cilia in the organization of stem cells and in
mediation of sonic hedgehog signaling. Without cilia,
radial astrocytes do not form and postnatal neurogenesis
fails. Dr. Buylla postulates that cilia mediate a SmoM2-
dependant tumorigenesis, which is an upstream mediator of
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suppress GLI2 dependant tumorigenesis, which is a
downstream transcriptional activator of sonic hedgehog
signaling. He reported that cilia can both mediate and
suppress medulloblastoma formation, depending on the
underlying oncogenic event and may represent an organelle
that is a potential target for therapy.
Trim3, the human homolog of Drosophila brat,
regulates neural differentiation, Myc expression,
and growth properties of gliomas
Dr. Daniel Brat (Emory University School of Medicine,
Atlanta, GA) reported on Human Tripartite motif protein
(Trim3), the human homolog of brat in Drosophila [13]. In
Drosophila, brat regulates asymmetric cell division of
neuroblasts. When it is mutated, undifferentiated neuro-
blasts accumulate as a tumor-like mass. In Drosophila, brat
appears to suppress Myc as its mode of action, which may
have correlates in human gliomas, since Myc is upregulated
in these tumors, at least partially following TP53 and
PTEN mutations. Dr. Brat’s group have also explored the
brat homolog (Trim 3b) in a vertebrate zebra ﬁsh model in
which Trim3 loss is also associated with a predominance of
neuroblastic cells. Using Rembrandt data, it was shown
that Trim3 is often lost in human gliomas and its loss is
associated with poor prognosis in low-grade gliomas.
Trim3 appears to be a candidate tumor suppressor in gli-
omas, as Trim3 is often down regulated or absent in glio-
blastoma and its loss is associated with greater growth
potential. Moreover, in vitro studies demonstrate that
Trim3 overexpression represses c-Myc in glioma cell lines
and inhibits proliferation [14].
Session 3: Modeling brain tumors in vivo
Chaired by W. K. Alfred Yung (UT M. D. Anderson
Cancer Center, Houston, TX).
Radiation resistance in brain tumors and the PI3K pathway
In this session, Dr. Eric C. Holland (Memorial Sloan-
Kettering Cancer Center, New York, NY) focused
speciﬁcally on a side population of glioblastoma that is
composed of endothelial and stem cells [15]. This glio-
blastoma subpopulation is enriched with neurosphere-
forming cells and is increased with PTEN loss. It also
appears that through selection, temozolomide increases this
phenotype of treated glioblastoma cells. It appears that this
PDGF? side-population of glioblastoma cells are highly
concentrated near blood vessels, and it was suggested that
this stem-cell likeness could be driven by the microenvi-
ronment of the peri-vascular niche. Some preliminary data
suggests that eNOS and active Notch1 are both upregulated
in PDGF gliomas and that perhaps nitric oxide may acti-
vate the notch signaling pathways in this subset of gliomas.
Dr. Holland suggested that nitric oxide drives the side
population phenotype in PDGF gliomas. Further work has
shown that nitric oxide functions through cGMP to activate
PKG and enhance the side population and notch signaling
and can also be blocked by PKG inhibitors. Recent work
has identiﬁed several GBM subtypes that can be deﬁned by
signaling characteristics, and the Proneural subgroup is
most consistent with gliomas driven by PDGF. This subset
of glioma tumor cells may identify new molecular targets
relating to chemotherapy/radiation resistance in cells near
the tumor vasculature. This nitric oxide notch pathway
needs to be further evaluated in EGFR? tumors, as well as
other glioblastoma subtypes.
Glioma stem cell and animal models
Dr. Luis F. Parada (UT Southwestern Medical Center,
Dallas, TX) discussed how animal models can provide
insights into the behavior of gliomas and glioma stem cells,
particularly genetic animal models. Ablation of NF1/p53
and PTEN can drive the formation of high-grade gliomas in
a mouse model; but interestingly, early lesions are asso-
ciated with the ventricles and the peri-ventricular space in
pre-symptomatic mice. Whereas the targeting of cells away
from the ventricular zone fails to induce gliomas, genetic
alterations such as NF1, p53, and PTEN deletions in the
stem-like cells in the ventricular zone can successfully
induce gliomas. Dr. Parada suggested that xenograft animal
models may greatly underestimate the percentage of tumor
initiating cells, and that these assays may not reﬂect the
physiology of tumors in the normal microenvironment.
Accurate and physiologically relevant genetic animal
models present an alternative to study and gain insights on
gliomas and glioma stem cells. Further work suggests that
both neural stem cells and glial progenitor cells can be
genetically altered to form gliomas [16]. There are many
lessons to learn from physiologically relevant animal
models of cancer, and it appears that the stem cell pro-
genitor compartment is a likely source of many brain
tumors.
A glioblastoma model using lentiviral vectors
In this proffered presentation, Dr. Dinorah Friedmann-
Morvinski (Salk Institute for Biological Studies, La Jolla,
CA) presented work on a novel glioma mouse model. This
lentiviral inducible mouse model in adult immunocompe-
tent mice is created by injecting Cre-loxP-controlled len-
tiviral vectors expressing oncogenes. GFAP region-speciﬁc
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subventricular zone and hippocampus were readily induced
to form glioblastoma when transduced, but the cortex
previously was not a commonly a site for inducible glio-
blastoma. Transplantation of brain tumor cells which
contained CD133? cells formed tumorspheres and could
differentiate into neurons and astrocytes when transplanted
into naı ¨ve mice brains and subsequently formed glioblas-
toma-like tumors [17]. Other studies are needed to evaluate
if CD133 is the best marker for these transplantable cells in
this animal model. Some data suggests that CD15 may be a
more appropriate identiﬁer for this subset of glioma cells.
This presentation suggested that Cre-loxP-controlled len-
tiviral vectors can generate a mouse glioblastoma model in
a region- and cell type-speciﬁc manner. Dr. Friedmann-
Morvinski also shared results with their new lentiviral
vector that expresses both the oncogene H-Ras and the
tumor suppressor sip53. Improving on their previous work,
they can now obtain glioblastoma-like tumors in all three
locations that were injected: hippocampus, sub-ventricular
zone and cortex.
Manipulating Drosophila glia to model human glioma
Dr. Renee D. Read (Salk Institute for Biological Studies,
La Jolla, CA) reviewed that Drosophila brain gene
expression is homologous to mammalian brain and can
lead to new insights. Activations of EGFR, RAS, and PI3K
cause neoplasia, but co-activation of EGFR and PI3K does
not elicit overgrowth from all neural cell types. Constitu-
tive co-activation of EGFR-Ras and PI3K pathways in
Drosophila glia and glial precursors gives rise to neoplas-
tic, invasive glial cells that create transplantable tumors
that model human glioma [18]. Further data demonstrates
that EGFR and PI3K mutations synergistically activate
several signaling pathways that lead to glioma induction in
Drosophila glial cells. These mechanisms contribute to cell
cycle entry, protein expression, and migration for these
Drosophila glial cells, which may represent a model for
identifying novel homologous human targets [18]. Lastly,
this live whole-body Drosophila model may permit pilot
screening of compounds and evaluation of novel drugs for
therapeutic efﬁcacy.
Session 4: Genomics and genetics of brain cancers
Chaired by Antonio Iavarone (Columbia University,
New York, NY).
Functionalizing the cancer genome
In this session, Dr. Lynda Chin (Dana-Farber Cancer
Institute, Boston, MA) reviewed the complex nature and
the redundancy in the function of various genetic altera-
tions and signaling pathways in glioma [19]. She discussed
the various patterns of Rb pathway inactivation in glioma
and noted that redundancy is the norm. Furthermore, she
showed that the speciﬁc pattern of Rb pathway inactivation
can be correlated with sensitivity to selective inhibitors
targeting core components of the Rb pathway, such as
CDK4/6. Other genetic mutations such as NF1 and p53
have been identiﬁed to be signiﬁcant in glioblastoma, and
the cancer genome analysis provides a systematic and
comprehensive analysis of the genetic alterations and sig-
naling pathways critical in the biology of glioblastoma.
Although there are a large number of candidates emerging
from large-scale cancer genome efforts such as TCGA,
functional validation and mechanical insight are required to
cull bystanders from drivers and to better understand the
biological relevance of these genomic alterations. High-
throughput functional validation and context-speciﬁc
analysis is required to functionalize the cancer genome
because of the extreme heterogeneity and complexity of the
glioblastoma cancer genome.
Developing targeted therapies for glioblastoma
Dr. Heidi S. Phillips (Genentech, Inc., South San Francisco,
CA) reviewed the prognostic subclasses of glioma: the
proneural, mesenchymal, and proliferative subtypes [20].
These subtypes have prognostic signiﬁcance, as overall
survival is poor in the proliferative and mesenchymal
groups and best in the proneural group. As novel targeted
therapies such as anti-angiogenic therapies are developed,
these biomarkers may identify which patients may be most
ideal for these therapies. To further advance the develop-
ment of glioma-targeted therapies, improved glioma models
must be developed. Tumor xenografts with their clear
borders do not accurately mimic inﬁltrative gliomas.
Although neurosphere grafts are invasive glioma models,
these tumor models lack angiogenesis, EGFR ampliﬁcation
and mesenchymal markers such as YKL40. There is a need
to develop novel glioma models that demonstrated both a
diffuse invasion pattern and the angiogenic phenotype.
Lastly, Dr. Phillips emphasized that the proneural group
with younger age and improved outcomes appear to be
correlated with the prognostic factor of IDH1 mutation.
Functional analysis of glioblastoma kinase mutations
found in TCGA: implications for targeted therapy
Dr. Matthew L. Meyerson (Dana-Farber Cancer Institute,
Boston MA) reviewed the importance of glioma thera-
peutic targets identiﬁed from the TCGA analysis. It may be
critically important in order to evaluate the beneﬁt of tar-
get alteration to genomically screen, select, and stratify
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peutics. For example, in the analysis of EGFR kinase,
which is ampliﬁed in many gliomas [21], the EGFR
inhibitors were not found to be effective in glioma clinical
trials, which were not stratiﬁed according to the presence
or absence of variations in EGFR expression. Nevertheless,
these kinases function as signiﬁcant regulators of cellular
activity and represent critical targets for anti-tumor ther-
apy. Genomic stratiﬁcation will identify which targeted
therapy will be most effective for which patients, and
should be used as an approach to stratify patients for
clinical trials. Also, the analyses of the TCGA results may
identify new targets for therapy against glioma, such as the
C terminus mutations in EGFR, NF1, PI3K, and AKT.
Genomic analysis may help identify which patients can
beneﬁt from EGFR kinase inhibitors or other targeted
therapies in the clinical trials of glioblastoma.
An analysis of copy-number changes across
multiple cancer types
In this talk, Dr. Rameen Beroukhim (Dana-Farber Cancer
Institute, Boston, MA) evaluated for common genetic
events across multiple cancer types. Over 2520 tissue
samples and 611 cell lines were all systematically analyzed
using a 250,000 single nucleotide polymorphism (SNP)
array platform in a high throughput fashion. Because SNPs
are common genetic variations in the genome, they can be
useful as genomic markers. This analysis found 82 deleted
regions and 76 ampliﬁed regions, which were common
among various cancer types. Many deletions tended to
affect the largest genes in the genome. Ampliﬁcations and
deletions often involved BCL2 family members, including
MCL1 and BCL2L1. Focal genetic events tend to be shared
across multiple cancer types. These copy number data will
be shared with the neuro oncology community on the
website www.broadinstitute.org in order to improve the
efﬁciency and limit the research effort redundancy. We
commend these efforts to increase the speed of information
dissemination, and the collaboration that tumorscape will
foster may lead to improved efﬁciencies in brain tumor
research [22].
Inferring miRNA–mRNA regulatory networks
in glioblastoma
In the ﬁnal proffered presentation of the afternoon,
Dr. Sachet A. Shukla (Dana-Farber Cancer Institute,
Boston, MA) utilized the context of likelihood of related-
ness (CLR) algorithm, an extension of the relevance net-
works class of algorithm [23], to evaluate the relationship
between miRNA and mRNA expression using TCGA
glioblastoma genomic data. Using 194 TCGA glioblastoma
samples with matched miRNA and mRNA expression,
CLR analysis deﬁned many novel associations, some spe-
ciﬁc to molecular subtypes deﬁned by transcriptome pro-
ﬁling. When ﬁltered with copy number data, several
miRNAs emerged with strong evidence of links to key
regulatory pathways in glioma. For example, consistent
with recent publication (PMID: 19773441), microRNA 34a
was related to the Notch signaling pathway in the regula-
tory network of glioblastoma. In summary, CLR network
analysis can identify and infer transcriptional and regula-
tory interactions in glioblastoma.
Session 5: Translational neuro-oncology: Targeted
therapies and resistance
Chaired by Terrance G. Johns (Monash Institute of Medical
Research, Clayton, VIC, Australia).
Targeting immune cells, cancer stem cells,
and metabolites in brain tumors
In this session, Dr. Linda M. Liau (University of California
Los Angeles, Los Angeles, CA) began by deﬁning the
clinical problem of glioblastoma and the difﬁculty in
treating the remaining inﬁltrating cells after surgical
resection. She reviewed the results from a clinical trial of a
dendritic cell-based vaccine for glioma [24] and found that
overall survival was correlated with induction of a cyto-
toxic T-cell (CTL) responses and decreased TGF-b2
expression [25]. In addition, dendritic cells can be opti-
mized utilizing a toll-like receptor (TLR-7) agonist, imiq-
uimod (Aldara
TM), which promotes dendritic cell survival,
trafﬁcking, and tumor-speciﬁc activation of T cells [26]. In
22 glioblastoma patients treated with a DC-based vaccine
in conjunction with TLR agonists, the median survival was
1049 days, which is signiﬁcantly greater than historical
controls in this unblinded, non-randomized clinical trial.
Interestingly, this trial did not have a selection bias towards
better outcome genotypes as only 6 out of the 22 patients
had a proneural gene expression pattern, with the remain-
der having the poorer prognosis proliferative and mesen-
chymal phenotypes. It appears that the mesenchymal
subtypes had the most signiﬁcant improvement in overall
survival after dendritic cell vaccine therapy. Dr. Liau also
presented data regarding the resistance of glioma stem cells
to conventional therapies and the recent ﬁnding that IDH1
mutant gliomas are associated with a putative onco-
metabolite, 2-hydroxyglutarate, which may represent a
potential new target for therapy that can be monitored
using advanced MR spectroscopic analysis.
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In this presentation, Dr. Roger Stupp (University of
Lausanne, Switzerland) focused on the clinician’s view of
targeted therapy and how targeting angiogenesis has
translated into clinical applications. Anti-VEGF therapy
appears to normalize vascular permeability [27], trans-
lating into rapid decrease of edema and radiographic
responses (decrease in contrast enhancement). However,
the tumor will activate alternative pathways and escape
mechanisms (invasion and migration) and may subse-
quently demonstrate a more aggressive phenotype [28].
These mechanisms require further elucidation, and com-
bined blockage of multiple pathways may be required.
Discontinuation of anti-VEGF therapy may be associated
with a rebound phenomenon leading to rapid clinical
deterioration. Dr. Stupp also discussed integrins, which
are heterodimeric transmembrane proteins that mediate
migration and attachment, as potential targets for anti-
glioma therapy. Cilengitide, a selective integrin inhibitor,
has been shown to decrease invasiveness in vitro and
shows synergy with radiation and with chemotherapy in
an animal model. Initial clinical data in recurrent and
newly diagnosed glioblastoma is promising, and larger
randomized trials are ongoing. Many of these targeted and
anti-angiogenic agents may work best in combination
with chemotherapy. As MGMT promoter methylation is
an indicator for sensitivity to alkylating agent chemo-
therapy, determination and stratiﬁcation or selection
according to the MGMT methylation status is of impor-
tance [29, 30].
PTEN tyrosine phosphorylation as a determinant
of response to EGFR inhibitors in glioblastoma
In this presentation, Dr. Tim Fenton (Ludwig Institute,
University of California San Diego, La Jolla, CA) reviewed
the relationship between EGFR and PTEN in gliomas [31],
and that loss of PTEN expression in GBM attenuates
responsiveness to EGFR kinase inhibitors. Cases of glio-
mas resistant to EGFR inhibitors despite having wild-type
PTEN could be explained by post-translational impairment
of PTEN. This group reported that PTEN phosphorylation
is correlated to Sac activation, which may demonstrate a
potential mechanism for post-translational modiﬁcation of
PTEN and for resistance to EGFR inhibitors despite a wild-
type PTEN genotype. Inhibition of the Src pathway with a
drug such as Dasatnib may increase the sensitivity and
response to EGFR inhibitors in gliomas. Restoration of
PTEN or modifying this post-translational alteration of
PTEN may mitigate EGFR inhibitor resistance in wild-type
PTEN glioma.
Mechanisms of evasive resistance to VEGF inhibition
in mouse models of glioblastoma
In her presentation, Dr. Gabriele Bergers (University of
CaliforniaSanFrancisco,SanFrancisco,CA)presenteddata
that hypoxia through HIF1-alpha is commonly present in
glioblastomas and stimulates the recruitment of vascular
progenitor cells and pro-angiogenic myeloid cells to the
tumor site, which facilitates neovascularization [32].
Although blocking neovascularization has demonstrated
encouraging results in glioblastoma patients, a clinical
challenge is the rebound and increased invasiveness after
anti-VEGF therapy. Blocking the VEGF pathway inhibits
angiogenesis, increases tumor apoptosis, and may increase
survival,butitalsoincreasestheinvasivenessofglioma[32].
VEGF may limit invasiveness of the tumor through VEGF
receptor-mediatedeffects.Inmousemodelsofglioblastoma,
anti-VEGF therapy may elicit tumor adaptation and tumor
progression to stages of greater malignancy, with increased
invasiveness and occasional distant metastasis [32]. Ablat-
ing the VEGF receptor also increases tumor invasiveness.
Thus, anti-VEGF therapies may alter the natural history of
gliomasintoa moreinvasiveand aggressive phenotype after
anti-angiogenic therapy. This alteration warrants further
studies, as the use of anti-angiogenic therapies continue to
increase in glioma treatment.
Pathway analysis of glioblastoma tissue after
pre-operative treatment with the EGFR tyrosine kinase
inhibitor geﬁtinib
In this proffered talk, Dr. Monika E. Hegi (University
Hospital Lausanne, Lausanne, Switzerland) evaluated the
effect of geﬁtinib on glioma. Epidermal growth factor
receptor (EGFR) is frequently ampliﬁed and overexpressed
in high-grade gliomas and represents an intriguing thera-
peutic target [33]. However, clinical trials with EGFR
inhibitors have not found signiﬁcant impact in the treatment
of high-grade gliomas, raising the question if the drugs
actually reach the target. Geﬁtinib acts as an ATP mimetic
agent, binding to the cytoplasmic ATP pocket domain and
blocking receptor phosphorylations and EGFR mediated
activation of downstream pathways. In patients treated pre-
operatively with geﬁtinib, high drug levels were reached in
the glioblastoma tissues and EGFR phosphorylation was
efﬁciently blocked. However, phosphorylation of key
downstream pathway constituents such as AKT seemed not
affected, suggesting that the activity of the pathway may not
be efﬁciently inhibited. Redundancy of the pathway and
negative feed-back loops may contribute to this effect. Fur-
ther studies are required to identify key players involved in
this treatment resistance in order to design effective com-
bination therapies for successful attenuation of the pathway.
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inhibition in glioblastoma therapy
In the ﬁnal presentation of this session, Dr. Clark C. Chen
(Dana-Farber Cancer Institute, Boston, MA) suggested that
EGRv3 over-expression may manifest in increased reliance
on DNA repair pathways. Radiation introduces DNA dam-
age and may be optimized using siRNA against DNA repair
genes. Poly-(ADP-ribose) polymerase (PARP1) catalyzes
the transfer of ADP and mediates DNA repair. Inhibition of
PARP1 through siRNA demonstrates increased radiosensi-
tization of EGFRv3-overexpressing U87 glioma cells in
vitro. This mechanism may be due to the increased accu-
mulation of reactive oxygen species in EGFR v3 over-
expressing cells. EGFR hyperactivity may induce DNA
damage accumulation, which is enhanced by PARP1 inhi-
bition. Interestingly, high expression of PARP1 trends with
poorer survival among EGFR-ampliﬁed and or EGFR-
mutated tumors. RNA interference (RNAi) of DNA repair
pathways may optimize radiation and chemotherapy adju-
vants again gliomas with further investigation. High-
throughput genetic screening may identify DNA repair
pathways that might contribute to uncovering glioma
vulnerabilities [34].
Session 6: Translational neuro-oncology:
drug delivery and imaging
Chaired by Darell D. Bigner (Duke Comprehensive Cancer
Center, Durham, NC).
Advances in imaging of patients with brain tumors
In this presentation, Dr. Sarah J. Nelson (UCSF Compre-
hensive Cancer Center, San Francisco, CA) reviewed the
potential for non-invasive biomarkers for assessing tumor
properties. Her research is currently focusing on image-
guided tissue collection with ex vivo analysis, which allows
correlation of imaging markers with tissue biologic anal-
ysis. Structural, vascular, and metabolic imaging modali-
ties are required to develop non-invasive biomarkers for
assessing treatment effects after radiation, chemotherapy,
and other novel glioma therapies. Diffusion imaging can be
utilized to identify tumor inﬁltration and distinguish tumor
recurrence from treatment effect. Dr. Nelson’s data sug-
gested that higher apparent diffusion coefﬁcient (ADC) on
diffusion MRI correlates with both increased tumor inﬁl-
tration and cellularity, which results in worse prognosis
[35]. Vascular parameters and metabolites, such as choline
and lactate, are other useful biomarkers for prognosis and
glioma progression. Future application of MR metabolic
imaging using hyperpolarized C-13-enriched agents may
be a promising new technology for radiographic evaluation
of glioblastoma [36]. Utilizing dynamic nuclear polariza-
tion in this manner has enabled the direct monitoring of
C-13 metabolites in vivo at a high signal-to-noise ratio and
may improve both the sensitivity and speciﬁcity of imaging
for assessing treatment effects in patients with glioma.
Potential of RNAi therapeutics for the treatment
of glioblastoma
In this session, Dr. Dinah Sah (Alnylam Pharmaceuticals,
Cambridge, MA) reviewed the feasibility of utilizing RNA
interference (RNAi) to inhibit any molecular target of
interest. Synthetic small interfering RNAs (siRNAs) har-
ness the endogenous RNAi pathway, and can be designed
to silence any gene through the cleavage and degradation
of its mRNA. After silencing a target with siRNA, the
durability of this effect appears to last for approximately
3 weeks. In vivo studies have demonstrated the ability of
lipid nanoparticle-formulated siRNAs to reduce tumor
burden in an orthotopic liver tumor model in mice, sup-
press the targeted mRNAs, and produce the expected
mRNA cleavage products, conﬁrming the RNAi mecha-
nism. CNS molecular targets have also been suppressed in
rats and non-human primates with direct intraparenchymal
brain delivery of siRNA, which suggests the potential of
this approach for anti-tumor therapy in gliomas.
Cancer-associated IDH1 mutations produce
2-hydroxyglutarate
In the ﬁnal presentation, Dr. Mark A. Bittinger (Agios
Pharmaceuticals, Cambridge, MA) reviewed that the
enzyme, isocitrate dehydrogenase 1 (IDH1) converts isoci-
trate to alpha-ketoglutarate, and that IDH1 mutations are
commonly found in low-grade gliomas and secondary
glioblastomas while relatively rare in primary glioblasto-
mas. IDH1 mutations are single base pair mutations that
mutate arginine 132 to histidine, and the mutant enzyme has
previously been demonstrated to harbor impaired oxidative
decarboxylation activity. Cells expressing mutant IDH1
were found to contain elevated levels of the metabolite
2-hydroxyglutarate [37]. This elevation of 2-hydroxygluta-
rate was shown to be due to a novel enzymatic activity
of mutant IDH1, which converts alpha-ketoglutarate into
2-hydroxyglutarate. Interestingly, increased 2-hydroxy-
glutarate levels have been shown to correlate with an
increased risk of malignant brain tumors in patients with
inborn errors of 2-hydroxyglutarate metabolism [37]. IDH1
mutations are correlated with high levels of 2-hydroxy-
glutarate in human gliomas and 2-hydroxyglutarate may be
a biomarker with important clinical value for prognosis, as
well as a tractable therapeutic target.
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